Genprex, Inc. (GNPX) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Genprex, Inc. is a clinical-stage gene therapy company focused on oncology (Reqorsa) and diabetes (GPX-002) treatments. This report covers the quarterly period ended September 30, 2024. The company is a smaller reporting company and non-accelerated filer. As of November 5, 2024, there were 8,508,068 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(4,315,987) | $(7,748,243) | $(16,780,701) | $(24,931,209) |
| Net Loss Per Share (Basic/Diluted) | $(1.23) | $(5.36) | $(6.90) | $(18.77) |
| Cash and Cash Equivalents (End of Period) | $1,488,281 | $11,711,319 | $1,488,281 | $11,711,319 |
| Accumulated Deficit | $(150,468,981) | $(127,759,028) | $(150,468,981) | $(127,759,028) |
| Operating Expenses (Total) | $4,323,438 | $7,786,327 | $16,838,437 | $25,088,832 |
| Net Cash Used in Operating Activities (YTD) | $(13,279,658) | $(19,774,740) | $(13,279,658) | $(19,774,740) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 44% in Q3 2024 compared to Q3 2023. This was driven by a 40% reduction in R&D expenses (due to CDMO changes and headcount reduction from 18 to 13 employees) and a 51% reduction in G&A expenses (due to reduced professional services and headcount reduction from 13 to 7 employees).
- Liquidity Decline: Cash and cash equivalents dropped from $6.7 million at year-end 2023 to $1.5 million at September 30, 2024, a decrease of approximately $5.2 million YTD.
- Capital Raising: The company raised approximately $8.0 million in net proceeds from financing activities YTD 2024, primarily through a registered direct offering in March 2024 ($5.8 million) and an At-The-Market (ATM) facility ($2.1 million).
- Accounting Change: The company changed its accounting principle for intellectual property expenditures, expensing costs rather than capitalizing them, resulting in a non-cash expense impact of approximately $800,000 in G&A.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash is estimated to fund operations only through December 2024. Additional financing is required to continue clinical trials.
- Clinical Progress:
- Acclaim-3 (SCLC): Phase 1 dose escalation completed for the 0.09 mg/kg group with no dose-limiting toxicities; escalated to 0.12 mg/kg. Phase 2 expansion expected to start in H2 2024.
- Acclaim-1 (NSCLC): Phase 2a expansion ongoing. Enrollment limited to patients with prior Tagrisso treatment only. Interim analysis expected H1 2025.
- Acclaim-2 (NSCLC): Enrollment ceased in August 2024 due to resource prioritization and enrollment challenges.
- Strategic Alternatives: The company is evaluating a potential spin-out of its diabetes program (GPX-002) into a wholly-owned subsidiary ("NewCo") by the end of 2024, subject to financing.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and lack of accounting depth. Remediation efforts are underway.
Investor Verification Checklist
- Cash Runway: Verify the timeline for raising additional capital, as current funds are projected to last only until December 2024.
- Spin-out Feasibility: Monitor the status of the proposed diabetes program spin-out and its impact on the parent company's asset base and valuation.
- Internal Controls: Review future filings for confirmation that material weaknesses in internal controls have been remediated.
- Clinical Milestones: Track enrollment numbers and safety data for the Acclaim-1 and Acclaim-3 trials, which are critical for future funding rounds.
- Dilution Risk: Assess the impact of ongoing ATM sales and potential future equity raises on existing shareholders.